The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Distribution Update

27 Jun 2005 06:00

Embargoed: 27 June 2004 Akers Biosciences, Inc. ("Akers" or the "Company") Re. UK Distribution Agreement Akers Biosciences, Inc. is pleased to announce the launch of a number of itsproducts in the UK through its UK distribution agent Advanced Rapid DiagnosticsLimited ("ARD"). ARD was established in order to penetrate the UK markets withAkers' growing range of products.The Company is already actively marketing a number of CE approved products inthe UK through ARD which, among others, include:Tests for `drugs of abuse'Akers has developed a suite of tests for `drugs of abuse' including tests foruse of methadone, heroine, cocaine, marijuana and ecstasy among others. Forthis product ARD is targeting the public service markets alongside retailbusinesses or, indeed, any organisation wishing to have the ability to performrapid tests on staff. The Company believes that there is significant potentialfor law enforcement agencies or educational establishments to adopt thesetests.Alcohol BreathalyzersARD is marketing Akers' range of alcohol breathalyzers in the UK to a range ofindustries, in particular transport businesses operating any form of vehicles,be they rail, air, road or sea. In addition to ensuring transportation safety,the use of these products may also positively impact insurance costs for thesebusinesses. ARD will also be looking to penetrate retail markets including highstreet pharmacies so that the public will have access to affordable tests toshow alcohol levels, with particular emphasis on self-regulation in the case ofdriving.PIFA‚® Heparin/PF4 test for heparin-induced thrombocytopenia and thrombosissyndrome (HITTS)Following increasing levels of penetration in the United States and Canada forthis test, the first rapid test for heparin/platelet factor-4 antibodies, ARDwill be initially targeting the private healthcare sector in the UK. Heparin isa widely used intravenous anticoagulant in the United Kingdom. Intravenousheparin is commonly used for the prophylaxis and treatment of thromboembolicdisease, as well as numerous other applications including certain types of lungand heart disorders, and during or after a variety of surgeries including openheart, bypass, dialysis and orthopedic procedures. Heparin is also used fordiagnostic and therapeutic interventional radiologic procedures. Akers' test isable to identify, almost instantly, patients at risk for developing HITTS as aresult of administering of heparin. This is particularly crucial in cases ofemergency surgery. Patients identified by the test as being at risk can beprescribed alternative drugs in order to avoid, potentially, fatal reactions toheparin.Cholesterol TestsBlood cholesterol consists of HDL cholesterol (often called "good cholesterol")and LDL cholesterol (often called "bad cholesterol"). The risk of heart diseaseis related to HDL levels, total cholesterol levels, and other risk factors. TheAkers Biosciences Tri-Cholesterol Test Kit is the only FDA-approved rapid assaythat provides a complete cholesterol profile of the patient, withsemi-quantitative determinations of high-density lipoprotein (HDL) cholesterol,low-density lipoprotein (LDL) cholesterol, and total cholesterol levels inwhole blood obtained from a finger stick. The test is designed for routinemonitoring of cholesterol levels right in a physician's office or directly athome.Dr. Raymond Akers, Chief Executive, Akers Biosciences, Inc. commented,"We are now enjoying very encouraging levels of sales for many of our productsin the United States and other parts of the world and I am delighted to beembarking upon an aggressive marketing and sales drive in the UK. As is thecase in the US, many of our products will be completely unique in the UK,enabling crucial tests to be performed rapidly and accurately. There is agrowing need for tests for alcohol levels and use of drugs of abuse all overthe world. Our tests in this area will enable people, particularly in thetransport and education industries to identify situations of abuse instantly.As for our PIFA Heparin PF-4 test, we believe this test will help save lives inthe UK. In addition, the medical industry can save millions of pounds inheparin-related law suits of patients who have suffered symptoms of a drugwhose prescription could have been avoided through identification of risk withour test and the prescription of an alternative."Dr. Raymond AkersChief Executive, Akers Biosciences, Inc.Tel. 020 7917 9476Barry ParkerChief Executive, Advanced Rapid Diagnostics LimitedTel. 0161 792 1112Ben SimonsHansard CommunicationsTel. 020 7245 1100ENDAKERS BIOSCIENCES INC
Date   Source Headline
26th Nov 20099:28 amRNSHolding(s) in Company
25th Nov 20099:21 amRNSDirectorate Change
24th Nov 20097:00 amRNSHolding(s) in Company
4th Nov 20097:00 amRNSTrading Statement
30th Sep 20097:00 amRNSHalf Yearly Report
29th Sep 20097:00 amRNSABI Signs Malaria Test Distribution Agreement
13th Jul 20095:29 pmRNSResult of AGM
26th Jun 20099:19 amRNSAnnual Report & Accounts
25th Mar 20097:00 amRNSDirector/PDMR Shareholding
24th Mar 20097:00 amRNSFinal Results
19th Mar 20093:26 pmRNSHolding(s) in Company
11th Mar 20097:00 amRNSNotice of Preliminary Results
8th Jan 20091:48 pmRNSGrant of Warrants - Replacement
8th Jan 200912:00 pmRNSGrant of Warrants
8th Jan 20097:00 amRNSTrading Update
5th Jan 20097:00 amRNSTechnology Transfer & Supply Agreement
3rd Dec 20087:00 amRNSABI Sells Tax Losses in State of NJ, USA
20th Nov 20087:00 amRNSU.S. Over-the-Counter Distribution Agreement
27th Oct 20087:00 amRNSDirectorate Change
16th Sep 20083:17 pmRNSDirector/PDMR Shareholding
8th Sep 20087:30 amRNSNew Diagnostics in Diabetes
8th Sep 20087:00 amRNSInterim Results
4th Aug 20087:00 amRNSNotice of First Half Results
14th Jul 20087:00 amRNSABI Licenses Lithium System
26th Jun 20087:00 amRNSABI Signs New Distribution Ag
12th Jun 20083:50 pmRNSPlacing Update
11th Jun 20087:00 amRNSAdditional Listing
4th Jun 20089:00 amRNSAnnual Report and Accounts
4th Jun 20087:00 amRNSOption Agreement
9th Apr 20087:00 amRNSDirector/PDMR Shareholding
7th Apr 20087:01 amRNSFinal Results
3rd Apr 20087:00 amRNSDirectorate Change
14th Mar 200811:31 amRNSIssue of Equity
14th Jan 200810:17 amRNSIssue of Equity
7th Jan 20084:20 pmRNSResolution of Litigation
20th Dec 20077:01 amRNSDirector/PDMR Shareholding
18th Dec 200712:01 pmRNSChange of Adviser
28th Sep 200710:41 amRNSTotal Voting Rights
28th Sep 20077:00 amPRNDirectors' Shareholdings & Additional Listing
27th Sep 20077:00 amPRNHalf-yearly Report
18th Sep 20077:00 amPRNUnited States Military Contract
17th Sep 20077:00 amPRNUnited States Military Contract
12th Sep 20077:00 amPRNUK Sales Agency Agreement
7th Sep 200712:52 pmRNSIssue of Equity
21st Aug 20075:07 pmRNSChange of Nominated Adviser
17th Aug 20072:04 pmRNSAIM Rule 26
9th Aug 20077:00 amPRNDirectorate Change
8th Aug 20076:24 pmPRNAGM Statement
2nd Aug 20077:00 amPRNNotice of Results
31st Jul 20079:22 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.